Navigation Links
Transposagen Receives Over $4.3M in Grants and Investment

LEXINGTON, Ky., June 21, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it is the recipient of over $2,975,426 in additional Small Business Innovation Research (SBIR) funding; $1,975,426 from the National Institutes of Health (NIH) and $1,000,000 from the KY Cabinet for Economic Development (CED). Transposagen's project titled: Creation of Hyperactive Transposons for Mutagenesis in Rodents will further develop Transposagen's piggyback(TM) DNA Modification System. The piggyBac(TM) technology and other Transposagen technologies, such as site-specific nucleases called XTN(TM) TALENs, are genome modification tools used for the creation of custom cell lines and rat and mouse models.


The NIH performs comprehensive external peer review using experts from academia and industry to assess the scientific merit, technical merit, and commercial application of the proposed technology. The following was stated in the NIH's Project Summary Statement, "Transposon mediated mutagenesis has the potential to generate knockout embryonic stem cells and rats for a large number of genes. These are likely to become powerful tools in the researchers' toolkit. Impact on a broad spectrum of research areas is likely to be huge and sustained."

"This most recent award from the NIH and the CED further validates the importance of Transposagen's core technologies," said Dr. Eric Ostertag, CEO of Transposagen Biopharmaceuticals, Inc. "The focus of this grant is the creation of genetically modified rat models for studying human disease. However, Transposagen also provides these technologies to researchers for the creation of nearly any type of genetic modification in any model organism or cell line."

As part of the conditions of the award from the CED, Transposagen was required to match the $1,000,000 grant with at least $1,000,000 in investment money. Transposagen raised over $1.3 million in its Series A investment round, mostly from local angel investors. Transposagen has received grant funding and investments of over $8.0 million since 2005.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen is dedicated to providing better disease models through genetic modification. Transposagen specializes in custom and off-the-shelf XTN(TM) site-specific nucleases, animal models, cell lines, stem cells and cutting-edge research tools and technologies to improve drug discovery and development research.

Jack Crawford
535 W. Second Street
Lexington, KY 40508
(315) 351-9115

Media Contact: Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115,

News distributed by PR Newswire iReach:

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GenoSpace Founder and CEO Receives "Champions of Change" Award from White House
2. Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval
3. AMRI Burlington Receives DEA Approval to Handle Controlled Substances
4. zuChem Receives Two Polyol Patents
5. Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission
6. IntelliCell BioSciences Receives US Patent for its Stem Cell Extraction Technology
7. Nanoelectronics Center at UT Austin receives $7.8 million grant
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
10. New York Blood Centers Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development
11. CardioDx Receives College of American Pathologists (CAP) Accreditation
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... metabolism. But unless it is bound to proteins, copper is also toxic to ... researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper ...
(Date:11/24/2015)... --> --> ... Synthesis Market by Product & Services (Primer, Probe, Custom ... RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - ... is expected to reach USD 1,918.6 Million by 2020 ... of 10.1% during the forecast period. Browse ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
Breaking Biology News(10 mins):